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Sunil V. Rao, MDA fundamental aspect of patient care is weigh-ing risks and beneﬁts when consideringtherapeutic options. For patients undergoing
percutaneous coronary intervention (PCI), the risks
and beneﬁts vary by clinical presentation and
complexity of coronary anatomy. In addition, the
type of adverse event evolves over time. During the
procedure, outcomes of interest are angiographic
success, traditionally deﬁned in terms of residual ste-
nosis and Thrombolysis In Myocardial Infarction
(TIMI) ﬂow, and mortality. Post-procedure, ischemic
outcomes, such as periprocedural myocardial infarc-
tion (MI) and stent thrombosis, are considered along
with bleeding and vascular complications. Almost
all therapies for PCI are evaluated in the context of
these risks. Because coronary stents are permanently
implanted devices, the window of risk extends well
beyond the hospitalization, 30 days, or even 1 year
post-procedure. Dual antiplatelet therapy (DAPT)
with aspirin and a P2Y12 receptor antagonist is the
foundation of treatment post-PCI to reduce the inci-
dence of ischemic events; however, reports of very
late (>1 year) stent thrombosis occurring after stent
implantation have created uncertainty in the clinical
community around its appropriate duration. This is
compounded by the risk associated with prolonged
DAPT—bleeding—that is also associated with a higher
incidence of stent thrombosis and mortality.SEE PAGE 1411In this issue of the Journal, Kazi et al. (1) use data
from a large integrated health system to assess out-
comes associated with spontaneous bleeding or MI*Editorials published in the Journal of the American College of Cardiology
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After adjustment, both bleeding and MI were associ-
ated with an increased risk for long-term mortality
with a similar degree of risk for both. Their ﬁndings
are consistent with the recent randomized DAPT
trial that evaluated 2 different durations of dual
antiplatelet therapy after PCI, demonstrating that
30 months of therapy reduced stent thrombosis and
major adverse cardiovascular and cerebrovascular
events at the expense of an increase in bleeding
(2). These ﬁndings broach several important clinical
questions: What are the mechanisms underlying the
association between bleeding and mortality? Can cli-
nicians determine which patients are at high risk for
bleeding? And, most importantly, what strategies
are available to reduce the risk for bleeding during
prolonged DAPT?
Figure 1 displays potential mechanisms that may
explain the consistent association of hemorrhagic
complications with mortality. Although intracranial
hemorrhage or frank exsanguination can be a proxi-
mate cause of death, these severe events are rare,
particularly in patients who survive hospitalization
for acute coronary syndrome or PCI. More commonly,
bleeding events during outpatient therapy are less
severe. Therefore, one explanation is residual con-
founding—patients who develop bleeding complica-
tions are likely different from those who do not
in measured and unmeasured ways. Patients who
bleed may have comorbidities or intervening events
that lead to mortality, and bleeding functions as a
marker for increased risk. The best way to differen-
tiate bleeding as a marker versus a mediator is
to randomize patients to bleeding or no bleeding.
Although this may seem implausible, the FEAST (Iron
[FE] and Atherosclerosis Trial) trial randomized pa-
tients with symptomatic peripheral arterial disease to
a regimen of scheduled phlebotomy (bleeding) versus
usual care to determine if reducing iron stores would
FIGURE 1 Potential Mechanisms Underlying the Relationship Between
Bleeding Complications and Mortality
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intervening events. DAPT ¼ dual antiplatelet therapy; ICH ¼ intracranial hemorrhage.
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1422reduce all-cause mortality (3). Patients assigned to
phlebotomy underwent removal of deﬁned volumes
of blood at 6-month intervals to reduce iron-
catalyzed free radical-mediated oxidative stress, but
avoid anemia. Over 6 years of follow-up, there was
no difference in mortality between the 2 strategies.
Of course, because spontaneous bleeding events in
patients on DAPT are neither regularly scheduled
nor result in a predeﬁned amount of bleeding, this
does not deﬁnitively prove or disprove a causal link
between bleeding and outcomes; however, random-
ized trials have shown that bleeding avoidance stra-
tegies in patients undergoing PCI are associated with
reduced mortality (4), suggesting a potential causal
link. The FEAST trial underscores that other mecha-
nisms are also likely. Foremost is discontinuation
of antiplatelet therapy that can occur even with
“nuisance” bleeding events. DAPT cessation may
then result in an increased risk for ischemic events
and death, especially from plaque ruptures unrelated
to the coronary stent (2). Although Kazi et al. (1)
attempted to adjust for antiplatelet use and timing,
their use of pharmacy data is a limitation because
patients may reﬁll prescriptions, but still not be
adherent to medications. Another potential explana-
tion for the association between bleeding and mor-
tality is that blood transfusion, rather than the
bleeding itself, may mediate the risk. Observational
studies in patients with acute coronary syndrome
and those undergoing PCI have demonstrated an as-
sociation between liberal use of transfusion and
increased mortality (5). Although these studies may
also suffer from confounding, randomized trials have
shown no beneﬁt of using blood transfusion tomaintain higher hemoglobin levels in other high-risk
populations, suggesting that routine, liberal use of
transfusion should be avoided until a randomized
trial of transfusion strategies in patients with active
ischemic heart disease is performed.
Despite the lack of clear data linking bleeding to
mortality, prevention of hemorrhagic complications
seems prudent. The ﬁrst step is to identify patients
at risk. Risk models for bleeding are available, but
many were developed in patients hospitalized with
acute coronary syndrome or undergoing PCI and
focus on in-hospital rather than post-hospital events.
These models consistently demonstrate that certain
patient characteristics are predictive: increasing age,
renal dysfunction, female sex, and pre-existing ane-
mia. Two models for bleeding during long-term
DAPT show some overlap with the inpatient models,
with age and renal function being associated with
“spontaneous” bleeding. Other important covariates,
such as concomitant use of oral anticoagulant agents
and the occurrence of surgical procedures during
therapy, also emerged as strongly associated with
hemorrhagic complications (6,7). Although using
these risk scores pre-procedure may help select pa-
tients in whom the risks of prolonged DAPT outweigh
the beneﬁts, true discrimination of bleeding and
ischemic risk is not yet achievable with currently
available models. There is signiﬁcant overlap in risk
factors for bleeding and MI (e.g., age and chronic
kidney disease); therefore, clinical judgment is still
important to avoid undertreating patients whose
ischemic risk outweighs bleeding risk.
It may be more important to universally use
bleeding reduction strategies in patients treated with
DAPT. The vast majority of signiﬁcant bleeding
events with oral antiplatelet therapy originate from
the gastrointestinal (GI) tract. Therefore, manage-
ment approaches aimed at reducing the GI bleeding
risk, including a reduction in the aspirin dose and
concomitant therapy with proton pump inhibitors
(PPIs), should be used in patients on long-term DAPT.
Although the optimal aspirin dose for treatment of
cardiovascular disease is unknown, the totality of
the data supports the use of a low-dose (<100 mg
daily) to reduce the risk of bleeding, while main-
taining efﬁcacy (8). With respect to PPIs, the COGENT
(Clopidogrel and the Optimization of Gastrointes-
tinal Events) trial compared aspirin þ clopidogrel þ
omeprazole with aspirin þ clopidogrel in patients
with an indication for DAPT (9). Although terminated
prematurely for lack of funding, COGENT demon-
strated that addition of omeprazole to aspirin and
clopidogrel signiﬁcantly reduced GI bleeding. Despite
the “black box” warning on the label for clopidogrel
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1423against concomitant use of omeprazole, a recent
systematic review showed that clopidogrel’s efﬁcacy
on clinical events is not reduced when prescribed
in combination with omeprazole (10), and concerned
clinicians can prescribe other available PPIs that
do not affect clopidogrel’s conversion to its active
metabolite. Another strategy is to use single anti-
platelet therapy with clopidogrel in PCI patients who
require chronic oral anticoagulation with a vitamin
K antagonist (11). Clinical trials are ongoing to deter-
mine the safety and efﬁcacy of such a strategy
in patients treated with novel oral anticoagulants.
Finally, it is essential to assess adherence to DAPT
during follow-up. Patients who stop DAPT in the
context of a bleeding event should restart therapy
as soon as clinically appropriate.The study by Kazi et al. (1) serves as a sobering
reminder that despite marked advances in phar-
macotherapy and PCI technology, clinicians and
patients still face the classic tradeoff between
reduction in ischemia and increased bleeding risk.
Prudent use of existing risk models and strategies
proven to reduce long-term bleeding risk, applied
in the context of clinical judgment, are key to
achieving the best long-term outcomes in patients
undergoing PCI.
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